Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds

Executive Summary

Merck/Schering-Plough's Vytorin is likely to have favorable formulary coverage with approximately 38% of managed care payors within the first year of launch, according to a survey by Prudential Equity Group
Advertisement

Related Content

Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority
Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority
Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Crestor European Label Changes Prompt FDA Public Health Advisory
Crestor European Label Changes Prompt FDA Public Health Advisory

Topics

Advertisement
UsernamePublicRestriction

Register

PS044560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel